Revenue: As of FY2026 Q2, the actual value is USD 15.04 M.EPS: As of FY2026 Q2, the actual value is USD 0.02.EBIT: As of FY2026 Q2, the actual value is USD 115 K.<h3>Second Quarter Financial Results</h3><ul><li>Total Revenue: $15.0 million, an increase of 11.5% compared to $13.5 million in the same period last year.</li><li>Oncology Services Profit: $7.8 million; Oncology Services Margin: 52%.</li><li>Net Income: $237,000, including $249,000 in stock-based compensation and $357,000 in depreciation and amortization expenses.</li><li>Adjusted EBITDA: $843,000, compared to $1.1 million in the second quarter of fiscal 2025.</li><li>Cost of Oncology Revenue: $7.3 million, a decline of $166,000 or 2.2% compared to $7.4 million in the same quarter of fiscal 2025.</li><li>Research and Development Expense: $2.6 million, an increase of $927,000 or 54.9% compared to $1.7 million for the same period last year.</li><li>Sales and Marketing Expense: $2.0 million, an increase of $247,000 or 14.1% compared to $1.8 million in the prior year period.</li><li>General and Administrative Expense: $3.0 million, an increase of $1.1 million or 57.4% compared to $1.9 million for the same period last year.</li><li>Net Cash Used in Operating Activities: - $1.9 million, primarily driven by an increase in accounts receivable and a decline in deferred revenue.</li><li>Cash on Hand: $8.5 million with no debt.</li></ul><h3>First Half Financial Results</h3><ul><li>Total Revenue: $29.0 million, an increase of 5.4% compared to $27.6 million for the same period last year.</li><li>Oncology Services Profit: $13.8 million; Oncology Services Margin: 47%.</li><li>Net Loss: - $230,000, including $457,000 in stock-based compensation, $715,000 in depreciation and amortization expenses, and a loss on the disposal of equipment of $20,000.</li><li>Adjusted EBITDA: $962,000, compared to $3.2 million in the first half of fiscal 2025.</li><li>Cost of Oncology Services: $15.3 million, an increase of $757,000 or 5.2% compared to $14.5 million for the same period in 2024.</li><li>Research and Development Expense: $4.7 million, an increase of $1.6 million or 49.5% compared to $3.1 million for the same period in 2024.</li><li>Sales and Marketing Expense: $3.9 million, an increase of $423,000 or 12.3% compared to the prior-year period.</li><li>General and Administrative Expense: $5.5 million, an increase of $1.1 million or 25.5% compared to $4.4 million for the same period in 2024.</li></ul><h3>Outlook / Guidance</h3><ul><li>Champions Oncology remains on track to deliver year-over-year revenue growth and achieve positive adjusted EBITDA for the full fiscal year.</li><li>The company is cautiously optimistic about the strengthening pharma and biotech funding environment, which should support improved bookings moving into calendar 2026.</li><li>Investments in the data platform and business development organization are expected to contribute meaningfully to long-term growth.</li></ul>

Champions Oncology | 8-K: FY2026 Q2 Revenue: USD 15.04 M